The glucagon‐like peptide‐1 receptor (GLP‐1R) agonists have shown great potential in treating diabetes mellitus, neurodegenerative diseases, obesity and hypertension. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.